To report an adverse event or product complaint, please contact us by phone at +1.833.582.4312

Posters & Presentations

This site includes ITF Therapeutics and Italfarmaco recent posters and oral presentations. The content contained in this site is subject to congress copyright permissions. Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. ITF Therapeutics does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.

Long-term Safety of Givinostat in Patients with Duchenne Muscular Dystrophy: Interim Results from an Open-label Extension Study
MDA
March 8-11, 2026

John F Brandsema, Gyula Acsadi, Federica Alessi, Paolo Bettica, Odile Boespflug-Tanguy, Michela Guglieri, Erika L, Finanger

For the Duvyzat Prescribing Information, view here.

Open-label Extension Analysis Shows Potential Delay in Age at Loss of Ambulation in Patients with Duchenne Muscular Dystrophy Treated with Givinostat
MDA
March 8-11, 2026

David Gomez Andres, Valeria Sansone, Andrea Parodi, Odile Boespflug-Tanguy, Natali Goedeker, Paolo Bettica, Tracey Willis, Eugenio Mercuri

For the Duvyzat Prescribing Information, view here.

Givinostat Reduces the Decline of Contractile Cross-sectional Area and Decreases Fat Infiltration in Patients with Duchenne Muscular Dystrophy
MDA
March 8-11, 2026

Krista Vandenborne, Rebecca Wilcocks, Paolo Bettica, Sara Cassaniga, Federica Alessi, Eugenio Mercuri

For the Duvyzat Prescribing Information, view here.

A Simplified Givinostat Dosing Regimen Minimizes Exposure Differences and Dose Reductions in Higher-Weight Patients
MDA
March 8-11, 2026

Eugenio Mercury, Francesco Bellanti, Sara Cassaniga, Paolo Bettica, Craig McDonald

For the Duvyzat Prescribing Information, view here.

Characterizing Platelet Count Reductions Below 75 x 10^9/L in Patients with Duchenne Muscular Dystrophy Treated with Givinostat from the Phase 3 EPIDYS Trial and LTSE Study
MDA
March 8-11, 2026

Michela Guglieri, Maria Cristina Scoto, Mary Jane Salinas, Andrea Parodi, Paolo Bettica, Erika L. Finanger

For the Duvyzat Prescribing Information, view here.

Characterizing Thrombocytopenia in Patients With Duchenne Muscular Dystrophy Treated With Givinostat: Results From the Phase 3 EPIDYS Trial
MDA
March 8-11, 2026

Laura McAdam, John F Brandsema, Erika L Finanger, Federica Alessi, Sara Zaxxaniga, Paolo Bettica, Erik H Niks

For the Duvyzat Prescribing Information, view here.

Characterizing Gastrointestinal Adverse Events of Interest From a Phase 3 Study of Givinostat in Patients With Duchenne Muscular Dystrophy
MDA
March 8-11, 2026

Liesbeth De Waele, John F Brandsema, Federica Alessi, Sara Zazzaniga, Paolo Bettica, Erika L Finanger

For the Duvyzat Prescribing Information, view here.

Cardiac Safety Data for Givinostat in Ambulant Patients with Duchenne Muscular Dystrophy: Results from the EPIDYS Study
MDA
March 8-11, 2026

Eugenio Mercuri, Barry J Byrne, Erik H Niks, Ulrike Schara-Schmidt, Tracey Willis, Theirry Le Tourneau, Odile Boespflug, Tanguy, Michela Guglieri, Nuria Muelas, David Gomez Andres, Han C Phan, Sergio Cesar Diaz, John Bourke, Sara Cazzaniga

For the Duvyzat Prescribing Information, view here.

Givinostat Reprograms TGFβ-Induced Fibrotic Networks in DMD Stromal Cells
MDA
March 8-11, 2026

Monica Forino, Andrea Ghiroldi, Christian Steinkuhler, Gianluca Fossati

For the Duvyzat Prescribing Information, view here.

Givinostat Weight-Based Flexible Dosing: Rationale and Efficacy at the Different Doses
MDA
March 8-11, 2026

Aravindhan Veerapandiyan, Federica Alessi, Sara Cazzaiga, Paolo Bettica, Eugenio Mercuri

For the Duvyzat Prescribing Information, view here.

Exploring Quality of Life in Duchenne Muscular Dystrophy: Insights From Qualitative Patient and Caregiver Interviews
ISPOR EU
November 9-12, 2025

Exploring Quality of Life in Duchenne Muscular Dystrophy: Insights From QualitativePatient and Caregiver Interviews Exploring Quality of Life in Duchenne Muscular Dystrophy: Insights From QualitativePatient and Caregiver Interviews Mindy Leffler, Marielle G. Contesse, Eugenio Mercuri, Francina Munell Casadesus, Mercedes Lopez Lobarto, Samantha Parker, Sara Cazzaniga, Nicoletta Coceani, Valerie Deroo5

For the Duvyzat Prescribing Information, view here.

Vastus Lateralis Fat Fraction is Associated with Functional Efficacy Endpoints in Patients with Duchenne Muscular Dystrophy Treated with Givinostat in EPIDYS
AANEM
October 29-November 1, 2025

Craig M. McDonald, Francesco Bellanti, Sara Cazzaniga, Paolo Bettica, Ulrike Schara-Schmidt, Eugenio Mercuri, Michela Guglieri, Nuria Muelas, Krista Vandenborne

For the Duvyzat Prescribing Information, view here.

Characterizing Thrombocytopenia in Patients With Duchenne Muscular Dystrophy Treated With Givinostat: Results From the Phase 3 EPIDYS Trial
AANEM
October 29-November 1, 2025

John Brandsema, Erika L. Finanger, Federica Alessi, Sara Cazzaniga, Paolo Bettica, Laura McAdam, Erik H. Niks

For the Duvyzat Prescribing Information, view here.

Characterizing Gastrointestinal Adverse Events of Interest From a Phase 3 Study of Givinostat in Patients With Duchenne Muscular Dystrophy
AANEM
October 29-November 1, 2025

Erika L. Finanger, Liesbeth De Waele, Federica Alessi, Sara Cazzaniga, Paolo Bettica, John F. Brandsema

For the Duvyzat Prescribing Information, view here.

Disease Progression Modeling in Duchenne Muscular Dystrophy: Delayed Decay in 4-Stair Climb With Givinostat Compared With Standard of Care
AANEM
October 29-November 1, 2025

Chamindra G. Laverty, Eugenio Mercuri, Federica Alessi, Sara Cazzaniga, Paolo Bettica, Anna Largajolli, Francesco Bellanti, Yann Péréon, Craig M. McDonald, Erika L. Finanger

For the Duvyzat Prescribing Information, view here.

Efficacy of Givinostat by Age (6–7 and >7 years): A Post Hoc Analysis of EPIDYS
AANEM
October 29-November 1, 2025

Chamindra G. Laverty, Federica Alessi, Nicoletta Coceani, Paolo Bettica, Dragana Vucinic

For the Duvyzat Prescribing Information, view here.

Patient-Reported Outcomes From a Phase 3 Study of Givinostat in Patients With Duchenne Muscular Dystrophy
AANEM
October 29-November 1, 2025

Laura McAdam, Federica Alessi, Nuria Muelas, Liesbeth De Waele, Katiana Gruppioni, Sara Cazzaniga, Paolo Bettica, Craig M. Zaidman

For the Duvyzat Prescribing Information, view here.

Modeling Disease Progression in Duchenne Muscular Dystrophy: Reduced Decline in Forced Vital Capacity With Givinostat Compared With Standard of Care
AANEM
October 29-November 1, 2025

Erika L. Finanger, Chamindra G. Laverty, Federica Alessi, Sara Cazzaniga, Paolo Bettica, Anna Largajolli, Francesco Bellanti, Yann Péréon, Craig M. McDonald, Eugenio Mercuri

For the Duvyzat Prescribing Information, view here.

Efficacy of Givinostat in the Off-Target Population of EPIDYS: A Subgroup Analysis
AANEM
October 29-November 1, 2025

Richard Finkel, Han C. Phan, Federica Alessi, Sara Cazzaniga, Paolo Bettica, Chamindra G. Laverty

For the Duvyzat Prescribing Information, view here.

Cardiac Safety Data for Givinostat in Ambulant Patients with Duchenne Muscular Dystrophy: Results from EPIDYS Study
AANEM
October 29-November 1, 2025

Eugenio Mercuri, Barry Byrne, Erik H Niks, Ulrike Schara-Schmidt, Tracey Willis, Thierry Le Tourneau, Odile Boespflug-Tanguy, Michela Guglieri, Nuria Muelas Gómez, David Gómez Andrés, Han C. Phan, Sergio César Díaz, John Bourke, Sara Cazzaniga

For the Duvyzat Prescribing Information, view here.

Confirm you are a US Healthcare Professional

You are about to enter a site that is for United States (US) healthcare professionals only. By selecting “Yes” below, you certify that you are a healthcare professional residing in the US and that you wish to proceed to the healthcare professionals only site.

Please note that the information provided within this site is for educational purposes only and is not intended to be promotional or to provide medical advice.

Talk with an MSL

Preferred Method of Contact(Required)
Sunshine Act(Required)